Bragar Eagel & Squire, P.C. said a class action has been filed against Replimune Group Inc. in the United States District Court for the District of Massachusetts on behalf of investors who purchased or otherwise acquired Replimune securities between October 20, 2025, and April 10, 2026, inclusive. The lawsuit alleges that Replimune and other defendants made materially false or misleading statements, or failed to disclose adverse information, concerning the company’s Biologics License Application, or BLA (application for approval of a biologic drug). The allegations include that study-design concerns previously communicated by the FDA (U.S. Food and Drug Administration) were not addressed, and that Replimune submitted data from an early, unplanned analysis of RP1-104 involving 40 patients, or 10% of the planned 400-patient enrollment. The complaint alleges that deficiencies in RPL-001-16 and RP1-104 were likely to cause the FDA to reject the BLA. Investors have until October 5, 2026, to apply to the court for appointment as lead plaintiff. Bragar Eagel & Squire partners Brandon Walker and Melissa Fortunato are accepting inquiries at no cost or obligation.